<DOC>
	<DOCNO>NCT00510822</DOCNO>
	<brief_summary>This multicenter study aim investigate safety efficacy cimicoxib , selective COX-2 inhibitor , combination sertraline compare sertraline combine placebo patient major depression . This clinical study base assumption adjunctive treatment major depression COX-2 inhibitor may beneficial .</brief_summary>
	<brief_title>Cimicoxib Treatment Major Depression ( SECIM )</brief_title>
	<detailed_description>Adult patient gender , age 18 60 year diagnose major depression psychiatrist HamD-17 score ≥ 22 enrol . All patient undergo wash period 3 day ( without e.g . medication antidepressant medication ) prior receive sertraline combine cimicoxib placebo . In exceptional case opinion investigator concomitant psychotic treatment need , 3 mg lorazepam daily additionally administrated period first two week treatment.Assessment HamD-17 perform trained psychiatric raters wash week 0 ( baseline ) prior treatment . If HamD-17 score decrease less 22 second rating patient exclude study.Patient must in-patients wash period first two week treatment . Upon recommendation investigator , participant become out-patients ambulatory care day clinic first two week treatment.At baseline ( week 0 ) patient randomise one follow treatment arm : · 50 mg sertraline ( one tablet/unblinded ) daily plus cimicoxib ( one tablet-50mg ) twice daily.· 50 mg sertraline ( one tablet/unblinded ) daily plus placebo ( one tablet ) twice daily If study visit 3 ( i.e . 3 week treatment ) baseline therapy dose 50 mg sertraline daily consider therapeutically sufficient ( increase HamD-17 20 % compare baseline ) , increase 100 mg daily discretion investigator . The decision investigator increase sertraline dose 100 mg daily allow study visit 3 permit time study.During double-blind period , study visit take place every week week 6 clinical psychiatric safety assessment perform . Four week end treatment investigator designees call patient capture information patient feel assess patient experience SAE/AEs ( e.g . hospitalisation ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<criteria>Major depression diagnose psychiatrist DSM IV TR : 296.2x single depressive episode 296.3x recurrent depressive episode HamD17 score ≥ 22 Psychotic depression , bipolar disorder , obsessive compulsive disorder , anxiety disorder , personality disorder , drug alcohol abuse , schizoaffective disorder , schizophrenia All DSM IV TR AxisI disorder except depression All DSM IV TR AxisII disorder without exception Unsuccessful treatment 2 antidepressant medication Concomitant use psychotropic drug , include mood stabilizer Immediate risk suicidal behaviour Women pregnant , breast feeding planning become pregnant course study , Women postmenopausal , surgically sterilize use effective method contraception Any history cardiovascular disease ( e.g . angina , heart attack , stroke , congestive heart failure ) , uncontrolled high blood pressure , document peripheral arterial insufficiency symptomatic , clinically significant claudication , history peripheral arterial embolism History coronary heart disease ( CHD ) heart disease History upper low gastrointestinal ( GI ) ulceration , perforation and/or obstruction History upper low GI bleed within previous year History inflammatory bowel disease Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Cimicoxib</keyword>
	<keyword>Cox-2 inhibitor</keyword>
	<keyword>Sertraline</keyword>
</DOC>